Sign in to continue:
Type a stock name or symbol, then select from the suggestions.
Posted on February 24, 2026 at 1:29 pm (GMT+8)
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Investors should review the full official filings and consult their own financial advisor before making any investment decisions. The information herein is based on the company’s 2025 Annual Report and subsequent disclosures, and may be subject to change or further clarification.
Summit Therapeutics Inc. 2025 Annual Report: Key Investor Highlights Summit Therapeutics Inc. 2025 Annual Report: Key Investor Highlights Overview Summit Therapeutics Inc. (Nasdaq: SMMT), a clinical-stage pharmaceutical company, has released its Annual Report on...
Marsh & McLennan Companies Announces \$600 Million Senior Notes Offering New York, February 19, 2026 – Marsh & McLennan Companies, Inc. (“MMC”), a global professional services firm, has announced the successful pricing and execution...
BayCom Corp Declares Quarterly Cash Dividend of \$0.30 Per Share BayCom Corp Announces Quarterly Cash Dividend, Offers Outlook for Investors WALNUT CREEK, California, February 19, 2026 – BayCom Corp (NASDAQ: BCML), the parent company...